SCHEMBL22194693

SCHEMBL22194693

N/C(=N\OC(=O)CCl)C1Cc2ccccc2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.39
MTNR1A P48039 1/20 0.38
MTNR1B P49286 1/20 0.38
HTT P42858 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
L3MBTL1 Q9Y468 4/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
MITF O75030 1/20 0.33
IDO1 P14902 1/20 0.33
FAAH O00519 1/20 0.33
ALDH1A1 P00352 1/20 0.33
P2RX7 Q99572 1/20 0.33
LMNA P02545 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22194699 1.00 XDH (0.39) XDHMTNR1AMTNR1BHTTTDP1
SCHEMBL22210200 0.78 AKR1C3 (0.42) XDHHTTTDP1L3MBTL1POLB
SCHEMBL28725215 0.78 AKR1C3 (0.42) XDHHTTTDP1L3MBTL1POLB
SCHEMBL22209939 0.77 KDM1A (0.39) XDHMTNR1AMTNR1BHTTALDH1A1
SCHEMBL22194696 0.73 MTNR1A (0.41) MTNR1AMTNR1BMAPTNPC1RAB9A
SCHEMBL22209882 0.71 SLC9A1 (0.42) HTTTDP1L3MBTL1POLBMAPT
SCHEMBL28725165 0.71 SLC9A1 (0.42) HTTTDP1L3MBTL1POLBMAPT
SCHEMBL14022832 0.71 MTNR1A (0.47) MTNR1AMTNR1BHTTMAPTNPC1
SCHEMBL22209972 0.70 TDP1 (0.40) TDP1L3MBTL1SMN1; SMN2
SCHEMBL22194854 0.70 NOTUM (0.38) XDHHTTTDP1L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 XDH 1297/4885MTNR1A 399/4885MTNR1B 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.